MAGE-4 (230-239)

MAGE-4 (230-239) is a synthetic peptide fragment derived from the Melanoma Antigen Gene 4 (MAGE-4) protein, specifically corresponding to amino acid residues 230 through 239. As a member of the MAGE protein family, this peptide represents a defined epitope region recognized for its immunological relevance and its expression in various tumor cell types. The sequence's unique biochemical properties and its association with antigen presentation pathways make it a valuable reagent for investigators exploring tumor immunology, antigen processing, and peptide-based assay development. Its defined structure and sequence specificity support rigorous experimental reproducibility and enable targeted interrogation of immune recognition mechanisms within the context of cancer research.

Epitope mapping: As a well-characterized MAGE-4 peptide fragment, this sequence is frequently utilized in epitope mapping studies to delineate the specific regions of the MAGE-4 protein that are recognized by cytotoxic T lymphocytes (CTLs) or monoclonal antibodies. By incorporating this peptide into binding assays or T cell activation protocols, researchers can dissect the molecular determinants underlying antigen-specific immune responses, aiding in the identification of immunodominant regions and potential immunotherapeutic targets.

Immunogenicity assessment: The peptide serves as a model antigen for evaluating T cell responses in vitro, particularly within the field of tumor immunology. Its defined sequence enables precise stimulation of antigen-specific T cells derived from patient samples or experimental models, facilitating the measurement of cytokine production, proliferation, and cytolytic activity. Such studies contribute to a deeper understanding of immune recognition of tumor-associated antigens and inform the selection of candidate epitopes for further translational research.

Vaccine candidate screening: Due to its origin from a tumor-associated antigen, the MAGE-4 (230-239) peptide is often incorporated into preclinical screening platforms designed to assess the immunogenic potential of peptide-based vaccine candidates. Its use in functional assays, such as dendritic cell loading and subsequent T cell activation, enables systematic evaluation of peptide presentation efficiency and immunostimulatory capacity, supporting the rational design of next-generation peptide vaccines.

Peptide-MHC binding studies: The defined sequence and length of this peptide make it an ideal substrate for major histocompatibility complex (MHC) binding assays. Researchers employ such peptides to investigate the affinity and stability of peptide-MHC complexes, which are critical parameters in understanding antigen processing and presentation. These studies underpin the development of predictive algorithms for epitope selection and facilitate the engineering of optimized peptide ligands for immunological applications.

Analytical assay development: The synthetic nature and sequence specificity of this MAGE-4 fragment support its use as a standard or control in a range of analytical techniques, including mass spectrometry-based peptide quantification, HPLC method validation, and immunoassay calibration. By providing a reliable reference material, it enhances the accuracy and reproducibility of analytical workflows that require precise peptide identification and quantitation, thereby contributing to robust experimental outcomes in peptide research and immunological assay development.

1. Identification, Localization in the Central Nervous System and Novel Myostimulatory Effect of Allatostatins in Tenebrio molitor Beetle

2. Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

3. Olfactory receptor based piezoelectric biosensors for detection of alcohols related to food safety applications

4. Genetic, cellular, and structural characterization of the membrane potential-dependent cell-penetrating peptide translocation pore

5. Uncarboxylated osteocalcin decreases insulin-stimulated glucose uptake without affecting insulin signaling and regulators of mitochondrial biogenesis in myotubes